The OCTAVE trial is a multi-centre, multi-disease, prospective observational cohort trial that will seek to understand the immune response to SARS-CoV-2 vaccinations in patients with certain immunosuppressed conditions.

Cohorts include patients with chronic renal conditions, chronic liver conditions, inflammatory bowel disease, cancer (both solid and haematological malignancies), immune-mediated rheumatic/inflammatory conditions, haematopoietic stem cell transplant (HSCT) and chimeric antigen receptor (CAR) T recipients.

OCTAVE is a collaborative research project involving academic partners from the Universities of Glasgow, Birmingham, Oxford, Imperial College London and the IMPACT network. The project is funded by the Medical Research Council and is badged as an Urgent Public Health trial supported by the NIHR Clinical Research Network.

​

The Principal Investigator at the Oxford site is Professor Ellie Barnes, where the focus is on Gastrointestinal and Liver diseases.

The OCTAVE trial is a multi-centre, multi-disease, prospective observational cohort trial. A team of researchers from universities and hospitals in England and Scotland has begun research, known as the OCTAVE study, to discover the effectiveness of the COVID-19 vaccine in immunosuppressed and clinically at-risk patient groups. The researchers will build on years of experience in understanding the immune system in the context of chronic conditions. OCTAVE will help inform how best to vaccinate patients on immunosuppression, and protect them from COVID-19 infection in the future.

​

The OCTAVE study will investigate the effectiveness of COVID-19 vaccines being used in the UK in 2021. Up to 5,000 people with certain immunosuppressed conditions will be involved. Using a variety of state-of-the-art immune tests performed on blood samples taken before and/or after COVID-19 vaccination, researchers will determine patients’ COVID-19 immune response and, therefore, the likelihood that vaccines will fully protect these groups from future COVID-19 infection. Researchers have begun recruiting patients at sites across the UK, and will compare results from the study group against control groups of healthy people without underlying diseases who have also received COVID-19 vaccines.

The John Radcliffe Hospital in Oxford is recruiting specifically for the Liver and Inflammatory Bowel Disease (IBD) arm of the OCTAVE trial.

​

IBD patients on Biologics or Immunosuppression

• Infliximab

• Adalimumab

• Vedolizumab

• Ustakinumab

• Tofacitinib

• MTX/AZA/6-MP

Hepatology patients on Immunosuppression or Cirrhotic

• Liver transplant

• Liver Cirrhosis

• IgG4 Disease

• Autoimmune Hepatitis

• Hepatitis B

• Hepatitis C

We have started working on our follow up trial OCTAVE-DUO. The study aims to find out whether a SARS-CoV-2 booster vaccination can induce an adequate immune response in clinically vulnerable patients who have had a lower than average response to two doses of vaccine.

​

Keep checking back here for more updates.

Get in touch with OCTAVE to learn more about our work and how you can get involved.

Email: ouh-tr.octave@nhs.net

Tel: 07594 140184